LOXL2 and pancreatic ductal adenocarcinoma: Intriguingly, in pancreatic ductal adenocarcinoma, decreasing ECM with an anti–lysyl oxidase like-2 (anti-LOXL2) antibody in syngeneic orthotopic PDA mouse models accelerated tumor growth, resulting in diminished overall survival, which suggested a protective role of ECM (20).